**Research Projects / Clinical trials :-**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sr.no. | Title of Project | Sponsor / CRO | Phase of trial | Duration From  | Duration To | No.of patients enrolled | Amount Received  |
| 1 | Pain Management (Rofecoxib) |  | IV |  | 2002 | 10 |  |
| 2 | Osteoarthritis/Degenerative (Rofecoxib V/s Diclofenac) |  | IV |  | 2002 | 20 |  |
| 3 | Pain Management (Naproxen)  |  | IV |  | 2005 | 20 |  |
| 4 | Pain Management (Nimesulide)  |  | IV |  | 2007 | 100 |  |
| 5 | Muscoskeletal Spasm associated with low BACK pain (Zaltokin). |  | III b |  | 2011 | 30 |  |
| 6 | Osteoarthritis / Degenerative Disease (Etoricoxib) |  | IV |  | 2011 | 10 |  |
| 7 | Evaluation of Efficacy & Tolerability of a fixed Dose Combination of Eperisone Hydrochloride & Diclofenac Sodium In The Treatment of Acute Musculoskeletal Spasm Associated with Low Back Pain :An observer Blind , Prospective,Randomized , Controlled Study. | EISAI Pharmaceuticals India Pvt. Ltd./ CRO- Clinsearch.(National ) | III b | 01/02/2011 | 03/05/2011 | 60 | Rs 2000 per patient (for 10 days) |
| 8 | OSKIRA 2- D4300C00002: Phase 3, Multicentre, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs. | AstraZeneca AB,Sweden./ CRO-Quintiles.(Global) | Phase III | 06/04/2011 | Till Date | 7 | Rs 2.37 Lakhs Per Patient(for 1 year) |
| 9 | OSKIRA-X-D4300C00005: A long-term Extension Study to assess the safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis. | AstraZeneca AB,Sweden./ CRO-Quintiles.(Global) | Phase III | 06/04/2011 | Till Date | 5 | Rs 1,58,864 Lakhs Per Patient (for 1 year) |
| 10 | A Multicentre ,Double-Blind, Vehicle Controlled ,Parallel-Group Study Comparing a Generic Diclofenac Sodium Topical Gel ,1% to Voltaren Gel (Diclofenac Sodium Topical Gel) 1% in the Treatment of Subjects with Osteoarthritis of the knee.  | Amneal pharmaceuticals, New York./ CRO-Quintiles. |  | Site Selected |  |  | Rs 25,428 per patient(For 4 months) |
| 11 | A control-Labeled ,prospective ,Randomized ,Parallel Group, Multicentric ,Phase III Clinical trial to Evaluate Efficacy & Safety of a FDC of Lornoxicam 16 mg SR + Thiocolchicoside 16 mg SR Tablet OD Compared with Thiocolchicoside 8 mg Capsule BID in Patients suffering from pain associated with Skeletal Muscular Spasm of any etiology.  | Inventia Healthcare pvt. Ltd. India./ CRO Nexus Clinical Research Pvt.Ltd. | Phase III | 31-05-12 | 01-08-12 | 64 | 1,500 per patient.(for 1 month) |
| 12 | A Randomized , Active –Control ,Prospective ,Parallel ,Multicenter, Comparative phase –III ,Clinical Study of Evaluate Efficacy ,Safety & Tolerability of Tapentadol 200 mg Sustained Release Tablet BID with Tapentadol 100 mg Tablet QID in Subjects Suffering with Chronic Pain of any etiology. | Inventia Healthcare pvt. Ltd. India./ CRO Nexus Clinical Research Pvt.Ltd. | Phase III | Feasibility Filled |  |  | 1,500 per patient.(for 1 month) |
| 13 | CORRONA Registry Study | CORRONA International ,LLC,USA/CRO –Icon Clinical Research . |  | Feasibility Filled |  |  |  |
| 14 | Tinefcon /61 /11: Randomized double blind ,Parallel group,Placebo Controlled ,Prospective ,Phase II Study to evaluate The Safety And Efficacy of TNF – Alpha Inhibitor Tinefcon In Subjects with Active Ankylosing Spondylitis. | Piramal Life Sciences Ltd./ CRO-Invocon Research Pvt. Ltd. | Phase II | Feasibility Filled |  |  |  |
| 15 | A phase III, Prospective ,Randomized , Interventional , Multicentre Double blind Study designed to asses the safety and tolerability of PTH in Postmenopausal Women suffering with osteoporosis. |  CRO-Makrocare Clinical Research ltd.  | Phase III | Feasibility Filled |  |  |  |
| 16 | A Randomized ,Double- blind ,Placebo controlled , Parallel ,Multicetre,Phase-II Study, To evaluate The Efficacy and Safety of ITOLIZUMAB administered intravenously in combination with background oral Methotrexate (MTX) or MTX and hydroxychloroquine ( HCQ) in patients with active Rheumatoid Arthritis ( RA) having an inadequate response to MTX/MTX+HCQ  | Clinigene International Ltd./CRO- Axiom Lifesciences Pvt.Ltd. | Phase II | Feasibility Filled |  |  |  |
| 17 | OA Knee. | CRO- Standev Research Pvt.Ltd. |  | Feasibility Filled |  |  |  |
| 18 | An investigator-blinded ,placebo-controlled ,randomized ,parallel group comparison of the effects of a single dose of Maxigesic (Paracetamol 325 mg + Ibuprofen 97.5 mg -3 tablets ) versus Nurofen (ibuprofen 400 mg) in participants with moderate to severe pain from removal of at least two third molars. | Synchron Research Services Pvt. Ltd. |  | Feasibility Filled |  |  |  |
| 19 | “A Randomized, Active-Control, Prospective, 2 Arm Parallel Group, Multicenter, Phase- III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Minodronic acid 50mg Tablet, Once Per 4 Weeks in comparison with Alendronic Acid 70mg Tablet, Once Weekly in Postmenopausal Women Diagnosed with Osteoporosis” | MSN Laboratories India Pvt.Ltd. | Phase III | Feasibility Filled |  |  | 3,500 per Patient |
| 20 | A Multicenter, Randomized ,Double-blind , Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab ),a Human Anti-IL-6 Monoclonal Antibody ,Administered Subcutaneously , in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy . | PAREXEL INTERNATIONAL Clinical Research Pvt. Ltd.(CRO- Janssen research & Development , LLC ) |  | Feasibility Filled |  |  |  |
| 2121 |  A Randomized, Double-Blind Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab | CRO - Quintiles |  | Feasibility Filled |  |  |  |
| 22 | A Randomized ,Double-blind , Placebo & active controlled, Parallel Group Study to evaluate the analgesic efficacy & safety of a fixed combination of dexketoprofen trametamol & tramadol hydrochloride on moderate to severe acute pain after unilateral elective total hip arthroplasty. | PAREXEL INTERNATIONAL Clinical Research Pvt. Ltd. |  | Feasibility Filled |  |  |  |
| 23 | CRECEL Study- Evaluation of clinical & linezolid combination  | FDC | IV | August 2012 | August 2012 | 2 |  |
| 24 | A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Patients with Moderate to Severe Rheumatoid Arthritis  | SAMSUNG BIOEPIS |  | Site Selected |  |  |  |
| 25 | A Multicentre, randomized, open lable, two period, two treatment, two way ,crossober, single dose, bioequivalence study compairing , Azathioprine tablets USP 50 mg strides arco lab limited (India) with Imuran 50 mg Azathiprine tablets USP 50 mg PROMETHUS LABORATORIES INC. in adults patients with Rheumatoid Arthritis under fasting conditions | Strides Arcolab Limited.Bangalore(INDIA). |  |  |  |  |  |